ClinicalTrials.gg
CompletedNCT04451720Updated Dec 5, 2022

Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis

A Phase 3 interventional study of Risankizumab and Placebo in Palmoplantar Pustulosis (PPP), sponsored by AbbVie. Completed at 39 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-05.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
20th of 30
119 · median 162
Started
2020
with 2 others
Phase 3
17 of 30
none open now
Registered
21st of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 20th largest by enrollment, is one of 3 that started in 2020, is one of 17 in phase 3, and was the 21st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

Palmoplantar pustulosis is a chronic inflammatory skin disease that causes repeated on and off symptoms like erythema (reddening, irritation), vesicle (swelling, cyst), pustules, scale, and crusts in palms and soles. This study evaluates how well risankizumab works compared to placebo (no medicine) to treat palmoplantar pustulosis. Study will assess change in Palmoplantar Pustulosis Area and Severity Index [PPPASI].

Risankizumab is an investigational drug being developed for the treatment of palmoplantar pustulosis. This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given study drug and who will receive placebo (no medicine). Participants are randomly put into 1 of 2 groups, called treatment arms to receive risankizumab or placebo in period A. In period B, each group receives both risankizumab and placebo at different time intervals. Around 116 adult participants with palmoplantar pustulosis will be enrolled in approximately 39 sites across Japan.

Participants will receive subcutaneous (SC) injections of risankizumab or placebo at Week 0 and Week 4 (Period A). Beginning Week 16 (Period B), both the groups will receive risankizumab and placebo at different intervals. Total treatment duration is 56 weeks.

There may be a higher burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Palmoplantar Pustulosis (PPP)

Browse trials for

Keywords

  • Palmoplantar Pustulosis (PPP)
  • Risankizumab
  • SKYRIZI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable moderate to severe Palmoplantar Pustulosis (PPP) with a Palmoplantar Pustulosis Area and Severity Index (PPPASI) total score of >= 12 at the Screening and Baseline Visits.
  • Moderate or severe pustules/vesicles on at least one palm or sole (>= 2 PPPASI severity score) at the Screening and Baseline Visits.
  • Experienced inadequate response (or intolerant) to treatment with topical and/or vitamin D3 derivative preparations and/or phototherapy and/or systemic etretinate.

Exclusion criteria

Exclusion Criteria:

  • History of active skin disease other than PPP which could interfere with the assessment of PPP.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Risankizumab

    In Period A, participants will receive risankizumab dose A at Weeks 0 and 4. In Period B, participants will receive risankizumab dose A at Weeks 16, 28, 40 and 52, and also placebo at Weeks 20, 32, 44 and 56.

    Drug: Risankizumab · Drug: Placebo

  • Experimental
    Placebo

    In Period A, participants will receive placebo at Weeks 0 and 4. In period B, participants will receive risankizumab dose A at Weeks 16, 20,32,44 and 56. and also placebo at Weeks 28,40 and 52.

    Drug: Risankizumab · Drug: Placebo

Interventions

  • Subcutaneous (SC) injection

    Also known as: SKYRIZI, ABBV-066

  • DrugPlacebo

    Subcutaneous (SC) injection

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score

    The Palmoplantar Pustulosis Area and Severity Index (PPPASI) assesses the severity of palmoplantar pustulosis lesions and their response to therapy. In the PPPASI system, the palms and soles are divided into 4 regions: the right palm, left palm, right sole, left sole which account for 20%, 20%, 30%, and 30%, respectively, of the total surface area of the palms and soles. Each of these areas are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPPASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.

    Time frame: Baseline (Week 0) through Week 16

Secondary outcomes

  1. Percentage of Participants Achieving at least 50% Improvement in PPPASI (PPPASI-50)

    The Palmoplantar Pustulosis Area and Severity Index (PPPASI) assesses the severity of palmoplantar pustulosis lesions and their response to therapy. In the PPPASI system, the palms and soles are divided into 4 regions: the right palm, left palm, right sole, left sole which account for 20%, 20%, 30%, and 30%, respectively, of the total surface area of the palms and soles. Each of these areas are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPPASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.

    Time frame: Baseline (Week 0) through Week 16

  2. Percentage of Participants Achieving at least 75% Improvement in PPPASI (PPPASI-75)

    The Palmoplantar Pustulosis Area and Severity Index (PPPASI) assesses the severity of palmoplantar pustulosis lesions and their response to therapy. In the PPPASI system, the palms and soles are divided into 4 regions: the right palm, left palm, right sole, left sole which account for 20%, 20%, 30%, and 30%, respectively, of the total surface area of the palms and soles. Each of these areas are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPPASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.

    Time frame: Baseline (Week 0) through Week 16

07

Study locations

39 sites
  • Ichinomiya Municipal Hospital /ID# 222581
    Ichinomiya-shi, Aichi 491-8558, Japan
  • Nagoya City University Hospital /ID# 221258
    Nagoya shi, Aichi 467-8602, Japan
  • Chukyo Hospital /ID# 218894
    Nagoya-shi, Aichi 457-8510, Japan
  • Fujita Health University Hospital /ID# 221285
    Toyoake-shi, Aichi 470-1192, Japan
  • Toho University Sakura Medical Center /ID# 220858
    Sakura-shi, Chiba 285-8741, Japan
  • Ehime University Hospital /ID# 221260
    Toon-shi, Ehime 791-0295, Japan
  • Kurume University Hospital /ID# 222751
    Kurume-shi, Fukuoka 830-0011, Japan
  • Fukushima Medical University Hospital /ID# 221639
    Fukushima-shi, Fukushima 960-1295, Japan
  • Gifu University Hospital /ID# 219109
    Gifu-shi, Gifu 501-1194, Japan
  • Ogaki Municipal Hospital /ID# 220801
    Ogaki-shi, Gifu 503-8502, Japan
  • Takagi Dermatology Clinic /ID# 220896
    Obihiro-shi, Hokkaido 080-0013, Japan
  • Bito Dermatology Clinic /ID# 222750
    Kobe-shi, Hyogo 651-0095, Japan
  • Meiwa Hospital /ID# 221633
    Nishinomiya-shi, Hyogo 663-8186, Japan
  • Ibaraki Prefectural Central Hospital /ID# 222712
    Kasama-shi, Ibaraki 309-1793, Japan
  • Mito Kyodo General Hospital /ID# 220799
    Mito-shi, Ibaraki 310-0015, Japan
  • Takamatsu Red Cross Hospital /ID# 221344
    Takamatsu-shi, Kagawa 760-0017, Japan
  • Tokai University Hospital /ID# 220945
    Isehara-shi, Kanagawa 259-1193, Japan
  • National Hospital Organization Sagamihara National Hospital /ID# 219082
    Sagamihara-shi, Kanagawa 252-0392, Japan
  • Yokohama City University Hospital /ID# 220860
    Yokohama-shi, Kanagawa 236-0004, Japan
  • University Hospital Kyoto Prefectural University of Medicine /ID# 221376
    Kyoto-shi, Kyoto 602-8566, Japan
  • National Hospital Organization Kyoto Medical Center /ID# 221772
    Kyoto-shi, Kyoto 612-8555, Japan
  • Mie University Hospital /ID# 221570
    Tsu-shi, Mie 514-8507, Japan
  • Tohoku University Hospital /ID# 219017
    Sendai-shi, Miyagi 9808574, Japan
  • Shinshu University Hospital /ID# 221343
    Matsumoto-shi, Nagano 390-8621, Japan
  • Nagasaki University Hospital /ID# 221141
    Nagasaki-shi, Nagasaki 852-8501, Japan
  • Nagaoka Red Cross Hospital /ID# 221375
    Nagaoka-shi, Niigata 940-2085, Japan
  • Isonokami dermatological clinic /ID# 219023
    Daito-shi, Osaka 574-0046, Japan
  • Kansai Medical University Kori Hospital /ID# 223096
    Neyagawa-shi, Osaka 572-8551, Japan
  • Osaka Metropolitan University Hospital /ID# 222012
    Osaka-shi, Osaka 545-8586, Japan
  • Kindai University Hospital /ID# 219022
    Osakasayama-shi, Osaka 589-8511, Japan
  • Kume Clinic /ID# 220869
    Sakai-shi, Osaka 5938324, Japan
  • Dokkyo Medical University Saitama Medical Center /ID# 222526
    Koshigaya-shi, Saitama 343-8555, Japan
  • Shizuoka Saiseikai Genaral Hospital /ID# 222427
    Shizuoka-shi, Shizuoka 422-8527, Japan
  • Dokkyo Medical University Hospital /ID# 221210
    Shimotsuga-gun, Tochigi 321-0293, Japan
  • St.Luke's International Hospital /ID# 219019
    Chuo-ku, Tokyo 104-8560, Japan
  • Teikyo University Hospital /ID# 221089
    Itabashi-ku, Tokyo 173-8606, Japan
  • The Jikei University Hospital /ID# 218822
    Minato-ku, Tokyo 105-8471, Japan
  • Tokyo Medical University Hospital /ID# 218893
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Seibo Hospital /ID# 221691
    Shinjuku-ku, Tokyo 161-8521, Japan
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Nov 2022, 28 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 28 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2020
First posted
Jun 30, 2020
StartActual
Jul 20, 2020
Primary completionActual
Nov 21, 2022
CompletionActual
Nov 21, 2022
Last update
Dec 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04451720
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 30, 2020
Start date
Jul 20, 2020
Primary completion
Nov 21, 2022
Completion
Nov 21, 2022
Last update
Dec 5, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion